Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.45p +6.16% 7.75p 8,981,145 14:01:42
Bid Price Offer Price High Price Low Price Open Price
7.50p 8.00p 7.75p 7.15p 7.30p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 2.5 -12.1 6.0 1.3 24.89

Premaitha (NIPT) Latest News

More Premaitha News
Premaitha Takeover Rumours

Premaitha (NIPT) Share Charts

1 Year Premaitha Chart

1 Year Premaitha Chart

1 Month Premaitha Chart

1 Month Premaitha Chart

Intraday Premaitha Chart

Intraday Premaitha Chart

Premaitha (NIPT) Discussions and Chat

Premaitha (NIPT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:15:007.161,111,11179,563.33O
16:07:297.751,450,000112,375.00O
15:24:157.55100,0007,550.00O
14:25:097.741,16289.94O
14:14:487.22500,00036,100.00O
View all Premaitha trades in real-time

Premaitha (NIPT) Top Chat Posts

DateSubject
25/5/2018
09:20
Premaitha Daily Update: Premaitha is listed in the Software & Computer Services sector of the London Stock Exchange with ticker NIPT. The last closing price for Premaitha was 7.30p.
Premaitha has a 4 week average price of 4.50p and a 12 week average price of 3.75p.
The 1 year high share price is 10.75p while the 1 year low share price is currently 3.75p.
There are currently 321,218,279 shares in issue and the average daily traded volume is 1,686,784 shares. The market capitalisation of Premaitha is £24,894,416.62.
11/5/2018
09:08
scrutable: a small number of small buys is moving the share price upwards every few minutes on only nine trades, this morning. An unusual pattern. Already up 0.7p by 9.00 am in very small steps. Is this recognition of strong undervaluation? I believe it will continue and added 30% to my holding yesterday. i am impatient to see the T/U promised for sometime in this month, expect to see persistent sales growth in all Far and Middle East territories, and hope that the recent registration in Brazil has also added sales as its huge population promises.
22/3/2018
13:18
ngen yap: Dear all, still (heavily) invested and watching on the sidelines. Share price very depressing and certainly not warranted, even if not surprising. I have not posted for a long time and probably not since the disappointing judgement. Since then, my decision to stay/accummulate/sell was dependent on a few key business critical checklist: New deals signed - this shows confidence of new customers despite the legal circumstance in the UK - we have had quite a few (4 x Europe, East Asia, ME, Egypt etc); Thermofisher support - they have come good with deposit / payment into Escrow account of £2.1m without warrants, pending appeal; UK specific nature of legal - company and outcome hearing in January confirmed this is UK only, and there has been no further writs from Illumina (yet and thankfully); Extent of exposure - looks like 10% of UK revenue + legal costs. This is manageable given gross margin in 40-50% even if painful! Break even / cash flow positive by year end - whilst not confirmed, I expect us to deliver this. We had £1.6m left as at end September. £0.6m R&D credit to come. Plus £1m from Thermo loan in February. That's £3.2m. If we are not nearly break even already, we will have raised more cash by now. So, four big ticks and one I expect to hear soon. Of course, we would all like settlement and to close this chapter. And we all know there has been a conscious effort from Premaitha to do so. Lots of talk about possible settlement now - this is a definite possibility but even in its absence, the process will help the EU Commission review and anti-trust defence, which then strengthens settlement route. I expect FY revenue to be circa £6.5 - £7m, growing to £11-12m in 2018/19. This based on existing deals. Brazil and China to come I reckon. I also suspect there are new products being developed and more than likely a new lab set up to process tests outside UK, powered by Thermofisher, as a counter measure. Stay positive and for the brave, buy! All the best.
13/3/2018
22:00
slartybartfaster: The mouse is nailed again by his nemesis, elrico. Caught out in his double standards. elrico 13 Mar '18 - 19:25 - 2106 of 2108 0.000050 3 0 Michaelmouse answered while he still avoids the elephant in the room. MM: Firstly, why does it take them 5 months to prepare relatively simple accounts for the year ending in November 2017? To fill the void, surely they could issue a brief trading statement with guidance on revenues and cash remaining? Most reputable companies don't have a problem with this. Me: 3 months, 5 months, it matters not as long as they fall within the 6 month reporting limit. And you shouldn't use the word "reputable" when invested in frauds (AVN, INTQ) and a company that has restated accounts (TRAKM8). OPTI usually report interims within 4 months and FY 5 months. This info is on the company website, as has been pointed out before. MM:Secondly, by now after announcing a number of agreements they must have some idea about revenues for 2018? Me: Another double standard...lets keep it simple shall we, 7DIG, AVN, TRAKM8, IND, STL; have any of these given revenue guidance for the year ahead? If they have, I missed them. In any event, OPTI is barely 6 months (accounting calendar) into transition from R&D to commercial yet, and many of the partnerships are wrapped up in NDA's, which has attributed to the stagemation thus far. Surely you should be applauding the BOD for not ramping up their book, as so many AIM companies do. In any event, how do you quantify sales in new markets, with new products, using new science? Please explain! MM: Thirdly, the figures are really all that matter presently. At a market cap. of £50m, the potential has already been "baked in" to the share price and has been for two years. The figures they publish still need to justify the current market cap. never mind justify substantial gains in the share price Me: To a degree, I guess I can allow a little leeway with this opinion. However, I would point to the industry valuation for SweetBiotix of £20+m, just 1 of several possible spinouts, and it has no commercial footprint yet, no commercial partner that we know of yet. I would also point out OptiBiotic platform has recently enhanced the LGG strain, the world's most popular probiotic...I'll spare your blushes by not mentioning the value of this strain. OPTI have several strains, which has real potential to be significantly more valuable.....in time. In short, the IP has real value, especially those commercialised via SlimBiome and LP-LDL. MM: Anyway, it's aimho. On a more positive note, if you truly believe in the company and its potential then just hang on in there over the long term, but carefully monitor the figures because ultimately they will drive the share price. The rest is all speculation on what could or might be. Me: Ah, we are aligned. You have long advocated trusting your research and hold long term. And yes of course, one should always monitor what the company says, read between the lines and pay particular attention to companies accounts, especially those that are forced to restate profits as losses....cough, cough! MM: That's all from me for a while. Me: It's probably best, you made a hash of that and I suspect you are perhaps a little concerned the level of partnerships may well prove worthy of rewarding those of use that stand by our research, speak to the company and look at the humanbiome sector and see perhaps what others do not. Don't feel pressured to respond...It's best you don't - keep your head down. ;) http://uk.advfn.com/cmn/fbb/thread.php3?id=35291865&fast_access=1
14/2/2018
11:30
gnnmartin: Interesting. At first glance it looks as thought Thermo Fisher hold as many as they can without triggering a bid, but I guess warrants don't count towards the 30% threshold unless they are exercised, and if they are exercised then the increase in shares means TF still 'only' hold 23%. When I first saw the announcement, I did not realise it was TF's holding, and I thought someone had built up a holding prior to a bid. Judging from the share price movement, several other people jumped to the same conclusion.
12/2/2018
07:05
humphries1: Premaitha Health Plc ("Premaitha" or the "Company") Thermo Fisher - issue of warrants Manchester, UK - 12 February 2018 - Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces that further to the notification made 12 July 2017 it has issued the Second Tranche of warrants to Thermo Fisher Scientific ("Thermo Fisher"). Thermo Fisher has been issued a warrant over 12,417,368 ordinary shares in the Company which may be exercised at a price of 5.775 pence per share, being 10% over the closing share price on 8 February 2018. In aggregate Thermo Fisher now hold warrants over 95,688,706 ordinary shares, representing 21% of the Company on a fully diluted basis. The Company has no further contractual commitments to issue warrants to Thermo Fisher. Following the issue of the warrants above, the Company has warrants over 98,511,560 ordinary shares in issue, including those of Thermo Fisher. In addition the Company has options over 38,991,232 ordinary shares. The issued share capital of the Company comprises 321,218,279 Ordinary Shares of 0.1p each. The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014 and has been arranged for release by Barry Hextall, Chief Financial Officer of the Company.
08/2/2018
09:26
pj 1: There WAS a support line at 7.4p, but that's well and truly gone. A good chance it could become resistance at some point in the future. Illumina have stated in effect they are going for the ''kill'' over the patent claim, one way or another NIPT have to eliminate this major Risk. Hence the share price.
06/2/2018
09:12
twix386: RnsPremaitha raises awareness at key conferences in middle East .Not going to do anything for the share price, but it all helps. Need a settlement with illumina......... "Dr Stephen Little, CEO of Premaitha Health, commented: "We continue to see increasing traction across the Middle East for the IONA® test. These key industry events will enable us to further raise awareness of both the IONA® test and the benefits of adopting NIPT, within a view to further enhancing our distribution networks in the region."
27/10/2017
08:08
twix386: Ngen,Yes, our share price is of course dragged back by the litigation.If we win we will re-rate and if as expected a mixed result we should rise significantly. All and only so long as we are not on the hook for costs and damages.And there is the reason we are sat with a share price rightly down here and not at 15p!!! If we gave to pay and raise funds and more dilution and/or consolidation that would wipe out existing investors then 15p is ridiculous for now and with such uncertainty.
20/10/2016
08:23
whites123: MAYA: Mayair Close to £5,500.000 still to spend on share buy back program. Averaged out that equates to over £1.40 per share, but all those bought lower means the upper price to pay can well exceed that marker. Tripling of the share price is easy once stock is in demand. Its a squeeze of epic proportions in the waiting. And yet another RNS from MAYA showing a further share buy back. Each and every time the rns comes out the price increases. Yesterday just 2 purchases. 1 from a PI buying 2,500 shares and the other purchase was a share buy back by the company. They have the mandate to buy approx a further 4 MILLION shares back. The share price will explode... Anyone else here excited about MAYA? (Mayair) They want to buy back 4,247,500 shares (10%) for a maximum of £5,755,750 They have already bought back 340,000 shares for £205,611 So they still have to buy back 3,907,500 shares with £5,550,139 They can pay up to 142p (£5,550,139 / 3,907,500) to acquire the outstanding stock but for every share they buy below 142p, they can pay more than 142p to complete the buy-back, so the price should keep stepping up. The objective of the buy back seems to be to get the share price up. This could triple from here. 19th Oct -2016 RNS today showing they bought back more shares.. In a lightly traded stock like this they have the mandate to buy back almost 4,000,000 more. Where will the share price be by then? Many many multiples of todays price is my best guess.
13/4/2015
13:24
the prophet: timmbo I agree with BlackSS, forget it, as it ain't going to add anything to £55m or whatever market cap NIPT. VIY didn't actually go bust, which was just as well, as it enabled Adam Reynolds to use VIY as a cash shell, but I know what you mean, BlackSS. For info, I think the IP is due to be returned to NIPT any day now, may even have happened. The focus is now clearly on NIPT, if there was any value in the IP, I'm sure Mr Reynolds will do what he can. imo, if we got £0.5m for it, that would be a bloody miracle. That would add, what, 0.25p onto the NIPT share price. That puts it in perspective! Move on is the best course of action, imo.
Premaitha share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180525 18:40:51